drugset / Trial / NCT00602030
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).
Timeline
- Start
- 2008-01-08
- Primary completion
- 2010-02-04
- Completion
- 2012-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entinostat | Small molecule | 5 mg | Oral |
| Subject | Entinostat | Small molecule | 10 mg | Oral |
| Background | Erlotinib | Small molecule | 150 mg | Oral |